ATE441710T1 - Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen - Google Patents
Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmenInfo
- Publication number
- ATE441710T1 ATE441710T1 AT04706034T AT04706034T ATE441710T1 AT E441710 T1 ATE441710 T1 AT E441710T1 AT 04706034 T AT04706034 T AT 04706034T AT 04706034 T AT04706034 T AT 04706034T AT E441710 T1 ATE441710 T1 AT E441710T1
- Authority
- AT
- Austria
- Prior art keywords
- hif
- inhibit
- expression level
- antisense oligonucleotides
- cell lines
- Prior art date
Links
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 title abstract 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 title abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44436703P | 2003-01-31 | 2003-01-31 | |
| PCT/US2004/002344 WO2004066949A2 (en) | 2003-01-28 | 2004-01-28 | Antisense oligonucleotides that inhibit expression of hif-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE441710T1 true ATE441710T1 (de) | 2009-09-15 |
Family
ID=35261932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04706034T ATE441710T1 (de) | 2003-01-31 | 2004-01-28 | Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7205283B2 (de) |
| EP (1) | EP1601325B1 (de) |
| KR (1) | KR101069521B1 (de) |
| CN (1) | CN100471862C (de) |
| AT (1) | ATE441710T1 (de) |
| BR (1) | BRPI0407070A (de) |
| CA (1) | CA2513398C (de) |
| DE (1) | DE602004022921D1 (de) |
| ES (1) | ES2333794T3 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| WO2005032486A2 (en) * | 2003-10-02 | 2005-04-14 | Duke University | A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY |
| US7618947B2 (en) * | 2004-08-25 | 2009-11-17 | Isis Pharmaceuticals, Inc. | Modulation of HIF-1 beta expression |
| US20100074897A1 (en) * | 2006-12-01 | 2010-03-25 | University Of Utah Research Foundation | Methods and Compositions related to HIF-1 alpha |
| US20080318241A1 (en) * | 2007-06-18 | 2008-12-25 | The Regents Of The University Of Michigan | Methods and Systems for Detecting Antiangiogenesis |
| US20110294868A1 (en) | 2010-04-29 | 2011-12-01 | Monia Brett P | Modulation of transthyretin expression |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| CN105163721B (zh) * | 2012-05-23 | 2018-05-22 | 俄亥俄州立大学 | 脂质纳米颗粒组合物以及制备和使用其的方法 |
| WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882914A (en) | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
| JP4638098B2 (ja) * | 1999-06-14 | 2011-02-23 | キャンサー・リサーチ・テクノロジー・リミテッド | 癌治療 |
| WO2002034291A2 (en) * | 2000-10-26 | 2002-05-02 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| SI2264172T1 (sl) * | 2002-04-05 | 2017-12-29 | Roche Innovation Center Copenhagen A/S | Oligomerne spojine za modulacijo izražanja HIF-1alfa |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
-
2004
- 2004-01-28 EP EP04706034A patent/EP1601325B1/de not_active Expired - Lifetime
- 2004-01-28 US US10/766,185 patent/US7205283B2/en not_active Expired - Lifetime
- 2004-01-28 AT AT04706034T patent/ATE441710T1/de not_active IP Right Cessation
- 2004-01-28 DE DE602004022921T patent/DE602004022921D1/de not_active Expired - Lifetime
- 2004-01-28 CA CA2513398A patent/CA2513398C/en not_active Expired - Fee Related
- 2004-01-28 ES ES04706034T patent/ES2333794T3/es not_active Expired - Lifetime
- 2004-01-28 BR BR0407070-4A patent/BRPI0407070A/pt active Search and Examination
- 2004-01-28 CN CNB2004800032331A patent/CN100471862C/zh not_active Expired - Fee Related
- 2004-01-28 KR KR1020057013673A patent/KR101069521B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2513398C (en) | 2013-09-10 |
| KR101069521B1 (ko) | 2011-09-30 |
| US20040152655A1 (en) | 2004-08-05 |
| US7205283B2 (en) | 2007-04-17 |
| CA2513398A1 (en) | 2004-08-12 |
| EP1601325A4 (de) | 2008-02-20 |
| BRPI0407070A (pt) | 2006-01-24 |
| EP1601325B1 (de) | 2009-09-02 |
| CN100471862C (zh) | 2009-03-25 |
| KR20050103476A (ko) | 2005-10-31 |
| ES2333794T3 (es) | 2010-03-01 |
| CN1809583A (zh) | 2006-07-26 |
| EP1601325A2 (de) | 2005-12-07 |
| DE602004022921D1 (de) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003151A (es) | Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata. | |
| BRPI0518228A (pt) | inibidores de cinesina mitótica e métodos de uso destes | |
| NL1025527A1 (nl) | Triazoolverbindingen die nuttig zijn in therapie. | |
| WO2007076423A3 (en) | INHIBITORS OF Akt ACTIVITY | |
| TW200612918A (en) | Lonidamine analogs | |
| EP1290005A4 (de) | Vegf-modulierte gene und verfahren, die diese verwenden | |
| NO20052701D0 (no) | Mikrobiocidiske stoffer. | |
| ATE441710T1 (de) | Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen | |
| AU300372S (en) | Personal care product | |
| WO2004016215A3 (en) | Use of antisense oligonucleotides to inhibit the expression of akt-1 | |
| NO20054053D0 (no) | Triazolforbindelser anvendbare i terapi. | |
| WO2004066949A8 (en) | Antisense oligonucleotides that inhibit expression of hif-1 | |
| PL1713438T3 (pl) | Mydło lecznicze | |
| CA102731S (en) | Fragrance dispenser | |
| IS7538A (is) | Prógestagena skammta einingar. | |
| ITMI20032037A1 (it) | Supporto del cruscotto. | |
| NO20053189D0 (no) | HVC-kombinasjonsterapi. | |
| ATE428786T1 (de) | Antisense-oligonukleotid mit antikrebsaktivität | |
| FR2858695B1 (fr) | Calculateur personnel. | |
| CA105222S (en) | Lavatory device | |
| BR0318204A (pt) | uso de nucleosìdeos 5-substituìdos | |
| UY29136A1 (es) | Uso de epotilonas en el tratamiento de metastasis osea | |
| BR8202549Y1 (pt) | disposição introduzida em suporte para chuveiros. | |
| ITRM20020372A1 (it) | Metodo di distribuzione di titoli con accredito differito, in particolare per ricariche telefoniche. | |
| ES1053847Y (es) | Perfeccionamientos introducidos en carteras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |